Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis - 01/01/04
pour le Comité Scientifique du GRIO1
pages | 6 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Antiresorptive agents are effective in preventing and treating postmenopausal osteoporosis, provided they are taken as directed. Regular physical examinations including height measurements may fail to ensure optimal compliance. Bone mineral density (BMD) measurement is indispensable for determining whether treatment is warranted. The measurement can be repeated after 2 years at least, provided quality-control procedures are adequate. BMD changes over time should be compared to the least significant change calculated from the in vivo BMD reproducibility at the measurement center. However, BMD changes are not correlated with the fracture risk reduction induced by antiresorptive treatment. Biochemical markers for bone turnover can be monitored after only 3-6 months provided steps are taken to control for intraindividual variability. They are useful when patient compliance is poor or the treatment response inadequate.
Le texte complet de cet article est disponible en PDF.Keywords : Postmenopausal osteoporosis, Bone markers, Bone densitometry, Estrogens, SERMS, Bisphosphonates
Plan
Vol 72 - N° 1
P. 26-31 - janvier 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?